President Donald Trump came into office promising to do something about the inflated prices Americans pay for prescription drugs. He considered limiting rebates to the middlemen between insurance plans and drug companies but recently concluded that the complex plan was unworkable.
This leaves policymakers back at square one. And it leaves Americans with a number of questions. Should they just resign themselves to paying more for their meds? Should they insist on price controls? Is there something in between?
